BACKGROUND: Results of CALGB 9741 demonstrated that administering standard doxorubicin/cyclophosphamide (AC)-paclitaxel therapy for adjuvant therapy of breast cancer in a dose-dense fashion with colony-stimulating factors increases efficacy, decreases severe neutropenia, but may increase the need for blood transfusions. A chart review was performed to evaluate the rates of anemia, neutropenia and skin toxicities with dose-dense and traditional AC-taxane chemotherapy. PATIENTS AND METHODS: A total of 112 patients received one of four treatments: non-dose-dense AC-paclitaxel (NDD Pac), dose-dense AC-paclitaxel (DD Pac), non dose-dense AC-docetaxel (NDD Doc), or dose-dense AC-docetaxel (DD Doc). RESULTS: Transfusion rates were not increased in the dose-dense population; however, rates of grade 2-4 anemia (23% versus 0%, P=0.029), as well as erythropoietin use (58% versus 0%, P <0.0001), were significantly increased in the DD Pac group compared with the NDD Pac group. Grade 3 skin toxicities were significantly increased in the DD Doc group compared with the NDD Doc group (70% versus 11%, P <0.0001). CONCLUSIONS: These results demonstrate that dose-dense AC-taxane therapy may increase rates of anemia and the need for erythropoietin, and decrease rates of neutropenia. The utility of DD Doc appears limited by skin toxicities and its use outside of a clinical study should not be recommended.
BACKGROUND: Results of CALGB 9741 demonstrated that administering standard doxorubicin/cyclophosphamide (AC)-paclitaxel therapy for adjuvant therapy of breast cancer in a dose-dense fashion with colony-stimulating factors increases efficacy, decreases severe neutropenia, but may increase the need for blood transfusions. A chart review was performed to evaluate the rates of anemia, neutropenia and skin toxicities with dose-dense and traditional AC-taxane chemotherapy. PATIENTS AND METHODS: A total of 112 patients received one of four treatments: non-dose-dense AC-paclitaxel (NDD Pac), dose-dense AC-paclitaxel (DD Pac), non dose-dense AC-docetaxel (NDD Doc), or dose-dense AC-docetaxel (DD Doc). RESULTS: Transfusion rates were not increased in the dose-dense population; however, rates of grade 2-4 anemia (23% versus 0%, P=0.029), as well as erythropoietin use (58% versus 0%, P <0.0001), were significantly increased in the DD Pac group compared with the NDD Pac group. Grade 3 skin toxicities were significantly increased in the DD Doc group compared with the NDD Doc group (70% versus 11%, P <0.0001). CONCLUSIONS: These results demonstrate that dose-dense AC-taxane therapy may increase rates of anemia and the need for erythropoietin, and decrease rates of neutropenia. The utility of DD Doc appears limited by skin toxicities and its use outside of a clinical study should not be recommended.
Authors: Sukhwant N Singh; Yue Zhu; Saranya Chumsri; Susan Kesmodel; Bruce L Gilliam; David J Riedel Journal: Clin Breast Cancer Date: 2013-11-20 Impact factor: 3.225
Authors: Ming J Poi; Michael Berger; Maryam Lustberg; Rachel Layman; Charles L Shapiro; Bhuvaneswari Ramaswamy; Ewa Mrozek; Erin Olson; Robert Wesolowski Journal: Support Care Cancer Date: 2013-05-19 Impact factor: 3.603
Authors: Danielle Cristinne Azevedo Feio; Nayara Cristina Lima de Oliveira; Edmundo Luis Rodrigues Pereira; Aleksandra Tiemi Morikawa; José Augusto Pereira Carneiro Muniz; Raquel Carvalho Montenegro; Ana Paula Negreiros Nunes Alves; Patrícia Danielle Lima de Lima; Raul Cavalcante Maranhão; Rommel Rodríguez Burbano Journal: Int J Nanomedicine Date: 2017-05-18
Authors: Daniel S O'Neil; Nancy L Keating; Jean Marie V Dusengimana; Vedaste Hategekimana; Aline Umwizera; Tharcisse Mpunga; Lawrence N Shulman; Lydia E Pace Journal: J Glob Oncol Date: 2017-05-12